Analysis of clinical variables associated with progression free survival in NSCLC EGFR-mutant patients.

Clinical Predictive Factors associated with First Line EGFR-TKI Efficacy  in Advanced NSCLC Patients with EGFR Mutations

Minjiang CHEN
Yan XU
Jing ZHAO
Wei ZHONG
Mengzhao WANG

February 2019

Background and objective Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) hav...

Characteristics of included studies for indirect meta-analysis.

Yaxiong Zhang (629676)
Jin Sheng (629677)
Shiyang Kang (629678)
Wenfeng Fang (172072)
Yue Yan (522296)
Zhihuang Hu (522294)
Shaodong Hong (629679)
Xuan Wu (126953)
Tao Qin (177288)
Wenhua Liang (110687)
Li Zhang (8200)

September 2014

aExon of EGFR mutation means either exon 19 deletion or exon 21 L858R mutation.Abbreviatio...

Baseline and Trend of Lymphocyte-to-Monocyte Ratio as Prognostic Factors in Epidermal Growth Factor Receptor Mutant Non-Small Cell Lung Cancer Patients Treated with First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors

Chen Yu-Mu
Lai Chien-Hao
Chang Huang-Chih
Chao Tung-Ying
Tseng Chia-Cheng
Fang Wen-Feng
Wang Chin-Chou
Chung Yu-Hsiu
Wang Yi-Hsi
Su Mao-Chang
Huang Kuo-Tung
Chen Hung-Chen
Chang Ya-Chun
Lin Meng-Chih

August 2015

-mutant patients with NSCLC.-mutant NSCLC were included. The cut-off values for baseline and the 1-m...

Analysis of variables associated with overall survival in NSCLC EGFR-mutant patients.

Shih-Hsin Hsiao (106194)
H. Eugene Liu (501592)
Hsin-Lun Lee (501593)
Chii-Lan Lin (501594)
Wei-Yu Chen (316810)
Zhung-Han Wu (501595)
Sey-En Lin (382444)
Ling-Ling Chiang (501596)
Chi-Li Chung (106193)

December 2013

‡reference group was exon 21. EGFR: epidermal growth factor receptor, TKI: tyrosine kinase...

Analysis of clinial variables associated with treatment efficacy of EGFR TKI in NSCLC EGFR-mutant patients.

Shih-Hsin Hsiao (106194)
H. Eugene Liu (501592)
Hsin-Lun Lee (501593)
Chii-Lan Lin (501594)
Wei-Yu Chen (316810)
Zhung-Han Wu (501595)
Sey-En Lin (382444)
Ling-Ling Chiang (501596)
Chi-Li Chung (106193)

December 2013

‡reference group was exon 21. EGFR: epidermal growth factor receptor, TKI: tyrosine kinase...

Direct comparison of TKI versus chemotherapy in EGFR exon 21 L858R mutations cohort in terms of HR for PFS. CI = confidence interval; EGFR = epidermal growth factor receptor; HR = Hazard ratio; PFS = progression-free survival; TKI = tyrosine kinase inhibitor.

Yaxiong Zhang (629676)
Jin Sheng (629677)
Shiyang Kang (629678)
Wenfeng Fang (172072)
Yue Yan (522296)
Zhihuang Hu (522294)
Shaodong Hong (629679)
Xuan Wu (126953)
Tao Qin (177288)
Wenhua Liang (110687)
Li Zhang (8200)

September 2014

Direct comparison of TKI versus chemotherapy in EGFR exon 21 L858R mutations cohort in terms of H...

Multivariate analysis of progression-free survival and overall survival in patients with the EGFR mutation.

Dalong Wang (2851229)
Minghui Zhang (298745)
Xuan Gao (130773)
Lijuan Yu (659956)

June 2016

Multivariate analysis of progression-free survival and overall survival in patients with the EGFR...

Response to ‘Clinical outcomes in NSCLC patients with EGFR mutations: pooled analysis’

Paz-ares Et Al
J Cell
Mol Med
Claire Watkins
Yuri Rukazenkov

August 2016

Activating somatic mutations in the epidermal growth factor receptor (EGFR) gene define a distinct s...

Characteristics of included studies for direct meta-analysis.

Yaxiong Zhang (629676)
Jin Sheng (629677)
Shiyang Kang (629678)
Wenfeng Fang (172072)
Yue Yan (522296)
Zhihuang Hu (522294)
Shaodong Hong (629679)
Xuan Wu (126953)
Tao Qin (177288)
Wenhua Liang (110687)
Li Zhang (8200)

September 2014

aExon of EGFR mutation means either exon 19 deletion or exon 21 L858R mutation.bHR19/...

Association of the Expression of Mutant Epidermal Growth Factor Receptor Protein as Determined with Mutation-Specific Antibodies in Non-small Cell Lung Cancer with Progression-Free Survival after Gefitinib Treatment

Azuma, Koichi
Okamoto, Isamu
Kawahara, Akihiko
Taira, Tomoki
Nakashima, Kazutaka
Hattori, Satoshi
Kinoshita, Takashi
Takeda, Masayuki
Nakagawa, Kazuhiko
Takamori, Shinzo
Kuwano, Michihiko
Ono, Mayumi
Kage, Masayoshi

January 2012

IntroductionSomatic mutations in the epidermal growth factor receptor (EGFR) gene are associated wit...

Association between EGFR-mutant status and Erlotinib treatment with all-cause survival among patients diagnosed in 2010 with stage IV non-small cell lung cancer, Patterns of Care.

Lindsey Enewold (2832911)
Anish Thomas (2832914)

June 2016

Association between EGFR-mutant status and Erlotinib treatment with all-cause survival amo...

Different EGFR Gene Mutations in Exon 18, 19 and 21 as Prognostic and Predictive Markers in NSCLC: A Single Institution Analysis.

Rossi, Sabrina
D'Argento, Ettore
Basso, Michele
Strippoli, Antonia
Dadduzio, Vincenzo
Cerchiaro, Eleonora
Martini, Marco
Cassano, Alessandra (ORCID:0000-0002-3311-7163)
Barone, Carlo Antonio
Martini, Maurizio (ORCID:0000-0002-6260-6310)

January 2016

Abstract BACKGROUND: Mutations of epidermal growth factor receptor (EGFR) in non-small cell lung ...

Indirect comparison of EGFR exon 19 deletion versus EGFR exon 21 L858R mutation in TKI therapy cohort in terms of HR for PFS.

Yaxiong Zhang (629676)
Jin Sheng (629677)
Shiyang Kang (629678)
Wenfeng Fang (172072)
Yue Yan (522296)
Zhihuang Hu (522294)
Shaodong Hong (629679)
Xuan Wu (126953)
Tao Qin (177288)
Wenhua Liang (110687)
Li Zhang (8200)

September 2014

aHR19/21 of TKI represents HR19 exon deletion/exon 21 L858R mutation in TKI...

Predictors of outcomes in patients with EGFR-mutated non-small cell lung cancer receiving EGFR tyrosine kinase inhibitors: A systematic review and meta-analysis

Buonerba C.
Iaccarino S.
Dolce P.
Pagliuca M.
Izzo M.
Scafuri L.
Costabile F.
Riccio V.
Ribera D.
MUCCI, BRIGITTA
Carrano S.
Picozzi F.
Bosso D.
Formisano L.
Bianco R.
De Placido S.
Di Lorenzo G.

January 2019

Some commonly available patient or disease characteristics may be associated with progression-free s...

The Predictive Value of EGFR Status in Non-small Cell Lung Cancer Patients Treated with EGFR-TKIs

Jun CHEN
Hongyu LIU
Yuli WANG

April 2010

Epidermal growth factor receptor (EGFR) is a major molecular for target therapy. The epidermal growt...

Clinical Predictive Factors associated with First Line EGFR-TKI Efficacy  in Advanced NSCLC Patients with EGFR Mutations

Minjiang CHEN
Yan XU
Jing ZHAO
Wei ZHONG
Mengzhao WANG

February 2019

Background and objective Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) hav...

Characteristics of included studies for indirect meta-analysis.

Yaxiong Zhang (629676)
Jin Sheng (629677)
Shiyang Kang (629678)
Wenfeng Fang (172072)
Yue Yan (522296)
Zhihuang Hu (522294)
Shaodong Hong (629679)
Xuan Wu (126953)
Tao Qin (177288)
Wenhua Liang (110687)
Li Zhang (8200)

September 2014

aExon of EGFR mutation means either exon 19 deletion or exon 21 L858R mutation.Abbreviatio...

Baseline and Trend of Lymphocyte-to-Monocyte Ratio as Prognostic Factors in Epidermal Growth Factor Receptor Mutant Non-Small Cell Lung Cancer Patients Treated with First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors

Chen Yu-Mu
Lai Chien-Hao
Chang Huang-Chih
Chao Tung-Ying
Tseng Chia-Cheng
Fang Wen-Feng
Wang Chin-Chou
Chung Yu-Hsiu
Wang Yi-Hsi
Su Mao-Chang
Huang Kuo-Tung
Chen Hung-Chen
Chang Ya-Chun
Lin Meng-Chih

August 2015

-mutant patients with NSCLC.-mutant NSCLC were included. The cut-off values for baseline and the 1-m...

Analysis of variables associated with overall survival in NSCLC EGFR-mutant patients.

Shih-Hsin Hsiao (106194)
H. Eugene Liu (501592)
Hsin-Lun Lee (501593)
Chii-Lan Lin (501594)
Wei-Yu Chen (316810)
Zhung-Han Wu (501595)
Sey-En Lin (382444)
Ling-Ling Chiang (501596)
Chi-Li Chung (106193)

December 2013

‡reference group was exon 21. EGFR: epidermal growth factor receptor, TKI: tyrosine kinase...

Analysis of clinial variables associated with treatment efficacy of EGFR TKI in NSCLC EGFR-mutant patients.

Shih-Hsin Hsiao (106194)
H. Eugene Liu (501592)
Hsin-Lun Lee (501593)
Chii-Lan Lin (501594)
Wei-Yu Chen (316810)
Zhung-Han Wu (501595)
Sey-En Lin (382444)
Ling-Ling Chiang (501596)
Chi-Li Chung (106193)

December 2013

‡reference group was exon 21. EGFR: epidermal growth factor receptor, TKI: tyrosine kinase...

Direct comparison of TKI versus chemotherapy in EGFR exon 21 L858R mutations cohort in terms of HR for PFS. CI = confidence interval; EGFR = epidermal growth factor receptor; HR = Hazard ratio; PFS = progression-free survival; TKI = tyrosine kinase inhibitor.

Yaxiong Zhang (629676)
Jin Sheng (629677)
Shiyang Kang (629678)
Wenfeng Fang (172072)
Yue Yan (522296)
Zhihuang Hu (522294)
Shaodong Hong (629679)
Xuan Wu (126953)
Tao Qin (177288)
Wenhua Liang (110687)
Li Zhang (8200)

September 2014

Direct comparison of TKI versus chemotherapy in EGFR exon 21 L858R mutations cohort in terms of H...

Multivariate analysis of progression-free survival and overall survival in patients with the EGFR mutation.

Dalong Wang (2851229)
Minghui Zhang (298745)
Xuan Gao (130773)
Lijuan Yu (659956)

June 2016

Multivariate analysis of progression-free survival and overall survival in patients with the EGFR...

Response to ‘Clinical outcomes in NSCLC patients with EGFR mutations: pooled analysis’

Paz-ares Et Al
J Cell
Mol Med
Claire Watkins
Yuri Rukazenkov

August 2016

Activating somatic mutations in the epidermal growth factor receptor (EGFR) gene define a distinct s...

Characteristics of included studies for direct meta-analysis.

Yaxiong Zhang (629676)
Jin Sheng (629677)
Shiyang Kang (629678)
Wenfeng Fang (172072)
Yue Yan (522296)
Zhihuang Hu (522294)
Shaodong Hong (629679)
Xuan Wu (126953)
Tao Qin (177288)
Wenhua Liang (110687)
Li Zhang (8200)

September 2014

aExon of EGFR mutation means either exon 19 deletion or exon 21 L858R mutation.bHR19/...

Association of the Expression of Mutant Epidermal Growth Factor Receptor Protein as Determined with Mutation-Specific Antibodies in Non-small Cell Lung Cancer with Progression-Free Survival after Gefitinib Treatment

Azuma, Koichi
Okamoto, Isamu
Kawahara, Akihiko
Taira, Tomoki
Nakashima, Kazutaka
Hattori, Satoshi
Kinoshita, Takashi
Takeda, Masayuki
Nakagawa, Kazuhiko
Takamori, Shinzo
Kuwano, Michihiko
Ono, Mayumi
Kage, Masayoshi

January 2012

IntroductionSomatic mutations in the epidermal growth factor receptor (EGFR) gene are associated wit...

Association between EGFR-mutant status and Erlotinib treatment with all-cause survival among patients diagnosed in 2010 with stage IV non-small cell lung cancer, Patterns of Care.

Lindsey Enewold (2832911)
Anish Thomas (2832914)

June 2016

Association between EGFR-mutant status and Erlotinib treatment with all-cause survival amo...

Different EGFR Gene Mutations in Exon 18, 19 and 21 as Prognostic and Predictive Markers in NSCLC: A Single Institution Analysis.

Rossi, Sabrina
D'Argento, Ettore
Basso, Michele
Strippoli, Antonia
Dadduzio, Vincenzo
Cerchiaro, Eleonora
Martini, Marco
Cassano, Alessandra (ORCID:0000-0002-3311-7163)
Barone, Carlo Antonio
Martini, Maurizio (ORCID:0000-0002-6260-6310)

January 2016

Abstract BACKGROUND: Mutations of epidermal growth factor receptor (EGFR) in non-small cell lung ...

Indirect comparison of EGFR exon 19 deletion versus EGFR exon 21 L858R mutation in TKI therapy cohort in terms of HR for PFS.

Yaxiong Zhang (629676)
Jin Sheng (629677)
Shiyang Kang (629678)
Wenfeng Fang (172072)
Yue Yan (522296)
Zhihuang Hu (522294)
Shaodong Hong (629679)
Xuan Wu (126953)
Tao Qin (177288)
Wenhua Liang (110687)
Li Zhang (8200)

September 2014

aHR19/21 of TKI represents HR19 exon deletion/exon 21 L858R mutation in TKI...

Predictors of outcomes in patients with EGFR-mutated non-small cell lung cancer receiving EGFR tyrosine kinase inhibitors: A systematic review and meta-analysis

Buonerba C.
Iaccarino S.
Dolce P.
Pagliuca M.
Izzo M.
Scafuri L.
Costabile F.
Riccio V.
Ribera D.
MUCCI, BRIGITTA
Carrano S.
Picozzi F.
Bosso D.
Formisano L.
Bianco R.
De Placido S.
Di Lorenzo G.

January 2019

Some commonly available patient or disease characteristics may be associated with progression-free s...

The Predictive Value of EGFR Status in Non-small Cell Lung Cancer Patients Treated with EGFR-TKIs

Jun CHEN
Hongyu LIU
Yuli WANG

April 2010

Epidermal growth factor receptor (EGFR) is a major molecular for target therapy. The epidermal growt...

Clinical Predictive Factors associated with First Line EGFR-TKI Efficacy  in Advanced NSCLC Patients with EGFR Mutations

Minjiang CHEN
Yan XU
Jing ZHAO
Wei ZHONG
Mengzhao WANG

February 2019

Background and objective Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) hav...

Characteristics of included studies for indirect meta-analysis.

Yaxiong Zhang (629676)
Jin Sheng (629677)
Shiyang Kang (629678)
Wenfeng Fang (172072)
Yue Yan (522296)
Zhihuang Hu (522294)
Shaodong Hong (629679)
Xuan Wu (126953)
Tao Qin (177288)
Wenhua Liang (110687)
Li Zhang (8200)

September 2014

aExon of EGFR mutation means either exon 19 deletion or exon 21 L858R mutation.Abbreviatio...

Baseline and Trend of Lymphocyte-to-Monocyte Ratio as Prognostic Factors in Epidermal Growth Factor Receptor Mutant Non-Small Cell Lung Cancer Patients Treated with First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors

Chen Yu-Mu
Lai Chien-Hao
Chang Huang-Chih
Chao Tung-Ying
Tseng Chia-Cheng
Fang Wen-Feng
Wang Chin-Chou
Chung Yu-Hsiu
Wang Yi-Hsi
Su Mao-Chang
Huang Kuo-Tung
Chen Hung-Chen
Chang Ya-Chun
Lin Meng-Chih

August 2015

-mutant patients with NSCLC.-mutant NSCLC were included. The cut-off values for baseline and the 1-m...

Analysis of clinical variables associated with progression free survival in NSCLC <i>EGFR</i>-mutant patients.

Abstract

Extracted data

Analysis of clinical variables associated with progression free survival in NSCLC <i>EGFR</i>-mutant patients.

Abstract

Extracted data

Related items

Related items